Authors
Pellegrino Musto, Jon Salmanton‐García, Nicola Sgherza, Rui Bergantim, Francesca Farina, Andreas Glenthøj, Guldane Cengiz Seval, Barbora Weinbergerová, Valentina Bonuomo, Yavuz M Bilgin, Jaap van Doesum, Ozren Jaksic, Benjamín Víšek, Iker Falces‐Romero, Monia Marchetti, Julio Dávila‐Valls, Sonia Martín‐Pérez, Marcio Nucci, Alberto López‐García, Federico Itri, Caterina Buquicchio, Luisa Verga, Klára Piukovics, Milan Navrátil, Graham P Collins, Moraima Jiménez, Nicola S Fracchiolla, Jorge Labrador, Lucia Prezioso, Elena Rossi, Natasha Čolović, Stef Meers, Austin Kulasekararaj, Annarosa Cuccaro, Ola Blennow, Toni Valković, Uluhan Sili, Marie‐Pierre Ledoux, Josip Batinić, Francesco Passamonti, Marina Machado, Rafael F Duarte, Christian Bjørn Poulsen, Gustavo‐Adolfo Méndez, Ildefonso Espigado, Fatih Demirkan, Martin Čerňan, Chiara Cattaneo, Verena Petzer, Gabriele Magliano, Carolina Garcia‐Vidal, Shaimaa El‐Ashwah, Maria Gomes‐Da‐Silva, Antonio Vena, Irati Ormazabal‐Vélez, Jens Van Praet, Michelina Dargenio, Cristina De‐Ramón, Maria Ilaria Del Principe, Joyce Marques‐De‐Almeida, Dominik Wolf, Tomáš Szotkowski, Aleš Obr, Gökçe Melis Çolak, Anna Nordlander, Macarena Izuzquiza, Alba Cabirta, Giovanni Paolo Maria Zambrotta, Raul Cordoba, Pavel Žák, Emanuele Ammatuna, Jiří Mayer, Osman Ilhan, Ramón García‐Sanz, Martina Quattrone, Elena Arellano, Raquel Nunes‐Rodrigues, Ziad Emarah, Tommaso Francesco Aiello, Michaela Hanakova, Zdeněk Ráčil, Martina Bavastro, Alessandro Limongelli, Laman Rahimli, Francesco Marchesi, Oliver A Cornely, Livio Pagano
Publication date
2024/1
Journal
Hematological Oncology
Volume
42
Issue
1
Publisher
Wiley
Description
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) infection and subsequent coronavirus (20)19 disease (COVID‐19)‐related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID‐19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS‐CoV‐2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow‐up was 52 days for the entire cohort and 83 days for survivors. Three‐hundred and three patients died (24%) and COVID‐19 was the primary reason for death of around 89% of them. Overall survival (OS …
Total citations
20243
Scholar articles
P Musto, J Salmanton‐García, N Sgherza, R Bergantim… - Hematological Oncology, 2024
P Musto, J Salmanton-García, N Sgherza, R Bergantim… - HemaSphere, 2023